Related Experiment Video
Updated: Feb 25, 2026
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Factors Associated With Time to Site Activation, Randomization, and Enrollment Performance in a Stroke Prevention
Bart M Demaerschalk1, Robert D Brown1, Gary S Roubin1
1From the Department of Neurology, Mayo Clinic, Phoenix, AZ (B.M.D.); Department of Neurology, Mayo Clinic, Rochester, MN (R.D.B.); Department of Cardiology, Brookwood Medical Center, Birmingham, AL (G.S.R.); Department of Epidemiology, University of Alabama, Birmingham (V.J.H.); Department of Neurology, Mayo Clinic, Jacksonville, FL (E.C., K.M.B., M.E.L., T.G.B., J.F.M.); Department of Neurology, Medical University of South Carolina, Charleston (J.H.V.); Department of Neurology and Stroke Program, University of Miami Miller School of Medicine, FL (S.C.); Department of Surgery, University of Maryland, Baltimore (B.K.L.); and Department of Biostatistics, University of Alabama at Birmingham (G.H.).
Background And Purpose:
Multicenter clinical trials attempt to select sites that can move rapidly to randomization and enroll sufficient numbers of patients. However, there are few assessments of the success of site selection.
Methods:
In the CREST-2 (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trials), we assess factors associated with the time between site selection and authorization to randomize, the time between authorization to randomize and the first randomization, and the average number of randomizations per site per month. Potential factors included characteristics of the site, specialty of the principal investigator, and site type.
Results:
For 147 sites, the median time between site selection to authorization to randomize was 9.9 months (interquartile range, 7.7, 12.4), and factors associated with early site activation were not identified. The median time between authorization to randomize and a randomization was 4.6 months (interquartile range, 2.6, 10.5). Sites with authorization to randomize in only the carotid endarterectomy study were slower to randomize, and other factors examined were not significantly associated with time-to-randomization. The recruitment rate was 0.26 (95% confidence interval, 0.23-0.28) patients per site per month. By univariate analysis, factors associated with faster recruitment were authorization to randomize in both trials, principal investigator specialties of interventional radiology and cardiology, pre-trial reported performance >50 carotid angioplasty and stenting procedures per year, status in the top half of recruitment in the CREST trial, and classification as a private health facility. Participation in StrokeNet was associated with slower recruitment as compared with the non-StrokeNet sites.
Conclusions:
Overall, selection of sites with high enrollment rates will likely require customization to align the sites selected to the factor under study in the trial.
Clinical Trial Registration:
URL: http://www.clinicaltrials.gov. Unique identifier: NCT02089217.
Related Concept Videos
01:13Randomized Experiments
Simple randomization
Simple...
01:21Factors Affecting Drug Response: Overview
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
01:15Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
01:24Drug Toxicity: Risk factors
01:15Factors Affecting Drug Distribution: Organ Perfusion Rate
Perfusion rate-limited distribution relies on the...